Table 2.
Clinical Characteristics of the 70 Patients with IBD Who Had Received Vitamin D3 and Had Available Follow-up 25-(OH) Vitamin D, CRP, and Partial Mayo Score Data at 6 Months
| Characteristics | CD (n=29) | UC (n=41) | P-value |
|---|---|---|---|
| Age (yr) | 30.7±9.8 | 43.5±16.4 | <0.001 |
| Male sex | 23 (79.3) | 26 (61.9) | 0.157 |
| Smoking status | 0.001 | ||
| Current | 7 (24.1) | 4 (9.5) | |
| Former | 2 (6.9) | 1 (2.4) | |
| Never | 17 (58.6) | 12 (28.6) | |
| Unknown | 3 (10.3) | 24 (57.1) | |
| 25-(OH) vitamin D (ng/mL) | 11.08±3.63 | 11.46±4.11 | 0.690 |
| CRP (mg/dL) | 1.49±1.80 | 0.75±1.49 | 0.064 |
| Montreal classification: age of CD (yr) | - | - | |
| A1 (≤16) | 2 (6.9) | ||
| A2 (17–40) | 25 (86.2) | ||
| A3 (>40) | 2 (6.9) | ||
| Montreal classification: location of CD | - | - | |
| L1 (Terminal ileum) | 11 (37.9) | ||
| L2 (Colon) | 0 | ||
| L3 (Ileocolic) | 18 (62.1) | ||
| Montreal classification: behavior of CD | - | - | |
| B1 (Nonstricturing, nonpenetrating) | 17 (58.6) | ||
| B2 (Stricturing) | 6 (20.7) | ||
| B3 (Penetrating) | 6 (20.7) | ||
| Montreal classification: extent of UC | - | - | |
| E1 (Ulcerative proctitis) | 15 (35.7) | ||
| E2 (Left-sided UC) | 9 (21.4) | ||
| E3 (Extensive UC) | 17 (40.5) | ||
| Current medication | |||
| 5-Aminosalicylates | 21 (72.4) | 41 (100.0) | <0.001 |
| Corticosteroid | 5 (17.2) | 12 (29.3) | 0.254 |
| Immunomodulator | 13 (44.8) | 4 (9.8) | 0.001 |
| Anti-TNF-α agent | 3 (10.3) | 2 (4.9) | 0.389 |
Values are presented as mean±SD or number (%).